You are here

P&T News

December 28

Brand-name Reyataz (Bristol-Myers Squibb) generated annual sales of more than $400 million in 2017
The minimally invasive technology is a synthetic, resorbable bone-graft substitute

December 26

Agent increases BP in adults with septic or other distributive shock
An SGLT2 inhibitor and two fixed-dose combinations will be available in January and February 2018
The noninvasive technology is used in conjunction with breast-conserving treatment

December 21

FDA announces that four studies showed no increased risk of death
Accelerated approval for neoadjuvant use also converted to full approval
Recurrence-free survival superior to Yervoy in trial

December 20

Pfizer drug was previously indicated as second-line therapy
Approval granted well in advance of predicted PDUFA date

December 19

Luxturna is first gene therapy to target a disease caused by mutations in a specific gene
Decline may stem from trust in physicians or effort needed to obtain exemptions
Drug lowers intraocular pressure in open-angle glaucoma or ocular hypertension
Legal dispute between Shire and Roche over “patent infringement” began in May
Ultragenyx will present voucher to Novartis upon closing of transaction

December 18

Type-2 diabetes patients most likely to pass on metformin
Delivery of care also likely to change, leaders tell Aon
Mouse study shows mature cells can create precancerous lesions

Pages